MedTrace Logo

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection

NCT02765802 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-01-17

Study results available
· View outcomes & findings →

Summary

To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.

Conditions

  • Hepatitis D, Chronic

Interventions

DRUG

Peginterferon Lambda-1A

Sponsors & Collaborators

  • Eiger BioPharmaceuticals

    lead INDUSTRY

Principal Investigators

  • David Apelian, MD, PhD, MBA · Eiger BioPharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-19
Primary Completion
2018-07-20
Completion
2018-12-12
FDA Drug
Yes

Countries

  • Israel
  • New Zealand
  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02765802 on ClinicalTrials.gov